

Special Issue

Targeted Therapies/Targetable Molecules for Treatment of Cancer and Diseases That Could Predispose to Cancer

Message from the Guest Editors

This Special Issue will highlight target therapies and targetable molecules that could be availed for treatment of Cancer. The predominant features of cancer include dysregulated cellular proliferation, cell death, immunosuppressive factors, anti-cancer immune responses and angiogenesis leading to growth, invasion and metastases. Diseases that could predispose to cancer include but are not limited to Lynch syndrome, Li-Fraumeni syndrome, human papillomavirus (HPV) infection, Epstein-Barr virus (EBV) infection, *Helicobacter pylori* infection, *Opisthorchis viverrini* infection, Schistosomiasis, chronic diabetes, pancreatitis, ulcerative colitis and Crohn's disease. Targeted cancer therapies/targetable molecules include but not limited to hormone therapies, signal transduction inhibitors, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, and toxin delivery molecules. Targetable molecules include but not limited to transcription factors, signal transduction molecules, peptides, kinases, epigenetic regulatory proteins, DNA damage repair enzymes, and proteasomes.

Guest Editors

Dr. Prema Robinson

Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Prof. Dr. Miguel Muñoz

1. Pediatric Intensive Care United, Virgen del Rocío University Hospital, 41013 Seville, Spain
2. Research Laboratory on Neuropeptides (IBIS), Virgen del Rocío University Hospital, 41013 Seville, Spain

Deadline for manuscript submissions

closed (15 June 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/119967

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)